Table 1 Sociodemographic and clinical differences between genotyped and not-genotyped individuals.

From: The continuity of effect of schizophrenia polygenic risk score and patterns of cannabis use on transdiagnostic symptom dimensions at first-episode psychosis: findings from the EU-GEI study

Case/control sample N = 2627

GWAS—NO

GWAS—YES

Test statistics

N = 556

N = 2,071

(NFEP = 1130, Ncontrols = 1497)

(NFEP = 282, Ncontrols = 274)

(NFEP = 856, Ncontrols = 1215)

Case/control status

Case

274 (49.3)

856 (41.3)

χ2 (1) = 11.3; p = 0.001

Age

Mean (SD)

32.6 (11.5)

34.3 (12.4)

t(2,2642) = 2.9; p < 0.05

Gender

Male

299 (53.8)

1104 (53.3)

χ2 (1) = 0.03; p = 0.84

Self-reported Ethnicity

White

374 (67.3)

1520 (73.4)

χ2 (5 )= 8.5; p = 0.13

Black

78 (14)

226 (10.9)

 

Mixed

54 (9.7)

172 (8.3)

 

Asian

17 (3.1)

51 (2.5)

 

North African

19 (3.4)

57 (2.7)

 

Other

14 (2.5)

45 (2.2)

 

Country

United Kingdom

123 (22.1)

459 (22.2)

χ2 (5) = 78.7; p < 0.001

Holland

54 (9.7)

352 (17)

 

Spain

74 (13.3)

352 (17)

 

France

71 (12.8)

181 (8.7)

 

Italy

157 (28.2)

310 (15)

 

Brazil

77 (13.8)

417 (20.1)

 

Research Domain Criteria Diagnosis (case only sample)

Bipolar disorder

13 (4.7)

47 (5.5)

χ2 (4) = 3.3; p = 0.5

Major depression with psychotic features

18 (5.9)

32 (4)

 

Schizophrenia

84 (30.7)

306 (35.7)

 

Schizoaffective disorder

116 (42.3)

318 (37.1)

 

Unspecified psychosis

48 (17.5)

148 (17.3)